This study is currently not recruiting participants.
A Phase 2/3 Randomized Double-Blind Multicenter Multinational 4-Arm Controlled Dose-Ranging Study to Evaluate Efficacy and Safety of Telizumab (MGA031) FcR Non-Binding Anti-CD3 Monoclonal Antibody in Children and Adults with recent-Onset Type 1
Not Recruiting
18 years - 35 years
All
Phase
N/A
Brief description of study.
No Description Available
Detailed description of study
No Description Available
Eligibility of study
You may be eligible for this study if you meet the following criteria:
Conditions:
Age:
18 years - 35 years
Gender: All
Updated on
09 Feb 2012.
Study ID: 1010002417 (0810-05)
Interested in the study?
Select a study center that’s convenient for you, and get in touch with the study team.
